Fendler Timothy J, Spertus John A, Gosch Kensey L, Jones Philip G, Bruce Jared M, Nassif Michael E, Flint Kelsey M, Dunlay Shannon M, Allen Larry A, Arnold Suzanne V
From the Mid-America Heart Institute, Kansas City, MO (T.J.F., J.A.S., K.L.G., P.G.J., S.V.A.); University of Missouri-Kansas City (T.J.F., J.A.S., J.M.B., S.V.A.); Washington University School of Medicine, Saint Louis, MO (M.E.N.); University of Colorado School of Medicine, Aurora (K.M.F., L.A.A.); and Mayo Clinic of Rochester, MN (S.M.D.).
Circ Cardiovasc Qual Outcomes. 2015 May;8(3):285-91. doi: 10.1161/CIRCOUTCOMES.115.001856. Epub 2015 Apr 29.
After left ventricular assist device (LVAD) placement for advanced heart failure, increased cerebral perfusion should result in improved cognitive function. However, stroke (a well-known LVAD complication) and subclinical cerebral ischemia may result in transient or permanent cognitive decline. We sought to describe the incidence and predictors of cognitive decline after LVAD using a valid, sensitive assessment tool.
Among 4419 patients in the Interagency Registry for Mechanically Assisted Circulatory Support who underwent LVAD implantation between May 2012 and December 2013, cognitive function was assessed in 1173 patients with the Trail Making B Test before LVAD and at 3, 6, and 12 months. The test detects several forms of cognitive impairment, including subclinical stroke. Cognitive decline was defined as a clinically important increase during follow-up using a moderate Cohen d effect size of 0.5×baseline SD (32 s). The cumulative incidence of cognitive decline in the year after LVAD implantation, treating death and transplantation as competing risks, was 29.2%. In adjusted analysis, older age (≥70 versus <50 years; hazard ratio, 2.24; 95% confidence interval 1.46-3.44; P(trend)<0.001) and destination therapy (hazard ratio, 1.42; 95% confidence interval, 1.05-1.92) were significantly associated with greater risk of cognitive decline.
Cognitive decline occurs commonly in patients in the year after LVAD and is associated with older age and destination therapy. These results could have important implications for patient selection and improved communication of risks before LVAD implantation. Additional studies are needed to explore the association between cognitive decline and subsequent stroke, health status, and mortality in patients after LVAD.
在晚期心力衰竭患者植入左心室辅助装置(LVAD)后,脑灌注增加应能改善认知功能。然而,中风(一种众所周知的LVAD并发症)和亚临床脑缺血可能导致短暂或永久性认知功能下降。我们试图使用一种有效、敏感的评估工具来描述LVAD植入后认知功能下降的发生率和预测因素。
在2012年5月至2013年12月期间接受LVAD植入的机构间机械辅助循环支持注册中心的4419例患者中,对1173例患者在LVAD植入前以及植入后3、6和12个月时采用连线测验B进行认知功能评估。该测试可检测多种形式的认知障碍,包括亚临床中风。认知功能下降定义为随访期间使用中度Cohen d效应量0.5×基线标准差(32秒)的具有临床意义的增加。将死亡和移植视为竞争风险,LVAD植入后一年认知功能下降的累积发生率为29.2%。在多因素分析中,年龄较大(≥70岁与<50岁相比;风险比,2.24;95%置信区间1.46 - 3.44;P趋势<0.001)和目标治疗(风险比,1.42;95%置信区间,1.05 - 1.92)与认知功能下降风险显著相关。
LVAD植入后一年患者中认知功能下降常见,并与年龄较大和目标治疗相关。这些结果可能对患者选择以及LVAD植入前风险的更好沟通具有重要意义。需要进一步研究以探讨LVAD植入后患者认知功能下降与随后中风、健康状况和死亡率之间的关联。